Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
AGN211745 · 1 trial · 2 indications
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | Single intravitreal injection |
| 2 | EXPERIMENTAL | Single intravitreal injection |
| 3 | EXPERIMENTAL | Single intravitreal injection |
| 4 | EXPERIMENTAL | Single intravitreal injection |
| 5 | EXPERIMENTAL | Single intravitreal injection |
| 6 | EXPERIMENTAL | Single intravitreal injection |
| Name | Type | Description |
|---|---|---|
| AGN211745 | DRUG | 100microgram single intravitreal injection |
Inclusion Criteria: * Active AMD with Subfoveal CNV (classic and/or occult CNV) * CNV lesion thickness \>/= 250um by OCT assessment * Visual acuity in study eye of \</= 20/100 but not worse than 20/800 * Not eligible for or refused standard treatment Exclusion Criteria: * Females of childbearing ...
AGN211745 is an investigational small molecule being developed for age-related macular degeneration (AMD), specifically for subfoveal choroidal neovascularization secondary to AMD. It is administered via intravitreal injection. The drug is currently in Phase 1 clinical development and is not approved by the FDA.
AGN211745 is being developed by AbbVie Inc. (NYSE: ABBV). The company is conducting clinical trials to evaluate the drug as a potential treatment for age-related macular degeneration.
AGN211745 is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by the FDA and is still undergoing clinical trials to assess its safety and efficacy in patients with age-related macular degeneration.
AGN211745 has one completed Phase 1 clinical trial, NCT00363714, which was a dose escalation study of intravitreal injections in patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration. The trial enrolled 26 participants in the United States.
Yes, AGN211745 is also known as Sirna-027. The Phase 1 clinical trial NCT00363714 evaluated Sirna-027, which is the same drug as AGN211745, in patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration.